Safety of daily low-dose aspirin use during pregnancy in low-income and middle-income countries.
low- and middle-income countries
low-dose aspirin
potential side effects
pregnancy
preterm birth
safety
unexpected emergency medical visits
Journal
AJOG global reports
ISSN: 2666-5778
Titre abrégé: AJOG Glob Rep
Pays: United States
ID NLM: 101777907
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
entrez:
4
6
2021
pubmed:
5
6
2021
medline:
5
6
2021
Statut:
ppublish
Résumé
The daily use of low-dose aspirin may be a safe, widely available, and inexpensive intervention for reducing the risk of preterm birth. Data on the potential side effects of low-dose aspirin use during pregnancy in low- and middle-income countries are needed. This study aimed to assess differences in unexpected emergency medical visits and potential maternal side effects from a randomized, double-blind, multicountry, placebo-controlled trial of low-dose aspirin use (81 mg daily, from 6 to 36 weeks' gestation). This study was a secondary analysis of data from the Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas trial, a trial of the Global Network for Women's and Children's Health conducted in India (2 sites), Pakistan, Guatemala, Democratic Republic of the Congo, Kenya, and Zambia. The outcomes for this analysis were unexpected emergency medical visits and the occurrence of the following potential side effects-overall and separately-nausea, vomiting, rash or hives, diarrhea, gastritis, vaginal bleeding, allergic reaction, and any other potential side effects. Analyses were performed overall and by geographic region. Between the aspirin (n=5943) and placebo (n=5936) study groups, there was no statistically significant difference in the risk of unexpected emergency medical visits or the risk of any potential side effect (overall). Of the 8 potential side effects assessed, only 1 (rash or hives) presented a different risk by treatment group (4.2% in the aspirin group vs 3.5% in the placebo group; relative risk, 1.20; 95% confidence interval, 1.01-1.43; The daily use of low-dose aspirin seems to be a safe intervention for reducing the risk of preterm birth and well tolerated by nulliparous pregnant women between 6 and 36 weeks' gestation in low- and middle-income countries.
Sections du résumé
BACKGROUND
BACKGROUND
The daily use of low-dose aspirin may be a safe, widely available, and inexpensive intervention for reducing the risk of preterm birth. Data on the potential side effects of low-dose aspirin use during pregnancy in low- and middle-income countries are needed.
OBJECTIVE
OBJECTIVE
This study aimed to assess differences in unexpected emergency medical visits and potential maternal side effects from a randomized, double-blind, multicountry, placebo-controlled trial of low-dose aspirin use (81 mg daily, from 6 to 36 weeks' gestation).
STUDY DESIGN
METHODS
This study was a secondary analysis of data from the Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas trial, a trial of the Global Network for Women's and Children's Health conducted in India (2 sites), Pakistan, Guatemala, Democratic Republic of the Congo, Kenya, and Zambia. The outcomes for this analysis were unexpected emergency medical visits and the occurrence of the following potential side effects-overall and separately-nausea, vomiting, rash or hives, diarrhea, gastritis, vaginal bleeding, allergic reaction, and any other potential side effects. Analyses were performed overall and by geographic region.
RESULTS
RESULTS
Between the aspirin (n=5943) and placebo (n=5936) study groups, there was no statistically significant difference in the risk of unexpected emergency medical visits or the risk of any potential side effect (overall). Of the 8 potential side effects assessed, only 1 (rash or hives) presented a different risk by treatment group (4.2% in the aspirin group vs 3.5% in the placebo group; relative risk, 1.20; 95% confidence interval, 1.01-1.43;
CONCLUSION
CONCLUSIONS
The daily use of low-dose aspirin seems to be a safe intervention for reducing the risk of preterm birth and well tolerated by nulliparous pregnant women between 6 and 36 weeks' gestation in low- and middle-income countries.
Identifiants
pubmed: 34085052
doi: 10.1016/j.xagr.2021.100003
pmc: PMC8171270
mid: NIHMS1703397
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : NICHD NIH HHS
ID : UG1 HD076457
Pays : United States
Organisme : NICHD NIH HHS
ID : UG1 HD076465
Pays : United States
Organisme : NICHD NIH HHS
ID : UG1 HD076474
Pays : United States
Organisme : NICHD NIH HHS
ID : UG1 HD078439
Pays : United States
Déclaration de conflit d'intérêts
The authors report no conflict of interest.
Références
Lancet. 2020 Jan 25;395(10220):285-293
pubmed: 31982074
Semin Perinatol. 2010 Dec;34(6):408-15
pubmed: 21094415
Ann Intern Med. 2014 May 20;160(10):695-703
pubmed: 24711050
BMC Pregnancy Childbirth. 2017 May 3;17(1):135
pubmed: 28468653
Lancet. 2017 Dec 17;388(10063):3027-3035
pubmed: 27839855
Lancet. 2014 Jul 5;384(9937):29-36
pubmed: 24702835
Obstet Gynecol. 2015 Apr;125(4):876-884
pubmed: 25751215
Obstet Gynecol. 2016 Apr;127(4):689-698
pubmed: 26959198
Cochrane Database Syst Rev. 2019 Oct 30;2019(10):
pubmed: 31684684
Lancet Glob Health. 2019 Jan;7(1):e37-e46
pubmed: 30389451